Alcobra Of Israel Seeks $20 Million In U.S. IPO to Develop ADHD Drug
This article was originally published in PharmAsia News
Executive Summary
Israel's Alcobra has drafted a U.S. filing for a proposal to raise as much as $20 million through an initial public offering so it can develop an attention deficit hyperactivity disorder drug, MG01C.